Evaxion A/s vs Tscan Therapeutics
Tscan Therapeutics is the larger business, with $10.3m of revenue in fiscal 2025 against $7.5m for Evaxion A/s (1.4 times as much). Tscan Therapeutics grew faster (266.7% against 125.1%). Evaxion A/s kept more of each dollar of sales as profit: a net margin of -102.4% against -1256.8%. Tscan Therapeutics carries less debt relative to equity (26.4% against 32.5%).
| Latest fiscal year | Evaxion A/sEVAX, 2025 | Tscan TherapeuticsTCRX, 2025 |
|---|---|---|
| Revenue | $7.5m | $10.3m |
| Revenue growth | 125.1% | 266.7% |
| Net income | −$7.7m | −$130m |
| Operating margin | -122.7% | -1315.4% |
| Net margin | -102.4% | -1256.8% |
| Return on equity | -100.2% | -71.3% |
| Free cash flow | −$6.6m | −$140m |
| Cash | $23.2m | $152m |
| Total debt | $5.5m | $32.5m |
| Debt to equity | 32.5% | 26.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 142 |
| Market value | $24.8m | $24.4m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 3 buys, 0 sales |